PE's K Shaped Recovery: Megadeals Mask Deeper Cracks

What's New

Bain & Company's Global Private Equity Report 2026 reveals that private equity posted its second best year ever in 2025, with buyout deal value surging 44% to $904 billion and exit value jumping 47% to $717 billion. But the recovery was decidedly narrow. Just 13 deals above $10 billion drove 69% of the growth, overall deal count fell 6%, and distributions to LPs remained at multidecade lows for a fourth consecutive year. Bain characterizes the environment as a K shaped recovery, where a subset of elite funds is thriving while the broader industry grinds through the most difficult fundraising period in its history.

Why It Matters

The report signals that private equity has crossed a structural inflection point, not a cyclical dip. The tailwinds that powered the industry for nearly two decades (zero interest rates, rising multiples, cheap debt) are gone. Bain's central thesis, captured in the phrase "12 is the new 5," argues that deals now require roughly 12% annual EBITDA growth to hit target returns, up from just 5% a decade ago. This fundamentally changes the competitive equation for GPs, LPs, and the technology platforms that serve them.

Big Picture Drivers

• Megadeal concentration: The $56.6 billion Electronic Arts take private (the largest buyout in history) and 12 other $10B+ deals accounted for $274 billion of the year's gains, but sovereign wealth funds and corporates supplied most of the equity, leaving buyout dry powder largely untouched.

• Liquidity gridlock: Distributions as a percentage of NAV held at roughly 14% for a fourth straight year, an industry record, while 32,000 unsold portfolio companies worth $3.8 trillion sit on GP balance sheets.

• Fundraising squeeze: Buyout fundraising dropped 16% in 2025 and fund closings fell 23%, even as infrastructure (up 58%) and secondaries (up 11%) found traction with LPs stretched by undrawn commitments from the 2021 to 2022 boom.

• Compressed economics: Average management fees have fallen to 1.6% (down 20% from the traditional 2%), and median coinvestment demands of 33 cents per dollar of fee bearing capital translate to a 25% revenue reduction for GPs.

• Rising cost of alpha: Competing effectively now requires heavy investment in specialization, AI, professionalized investor relations, and operating capabilities, all while revenue per AUM declines.

By The Numbers

• $904B in global buyout deal value, up 44% YoY and the second highest total ever recorded.

• $1.3T in buyout dry powder sitting idle, with the majority from 2022 to 2023 fund vintages aging under deployment pressure.

• ~7 years average holding period at exit, up from 5 to 6 years historically, with 39% of companies now held more than five years.

• 79% of GPs surveyed expect purchase multiples to stay flat in 2026, removing multiple expansion as a return lever.

• 53% of LPs report being constrained from making new PE commitments due to existing undrawn obligations.

Key Trends to Watch

• Exit momentum building: The Medline IPO ($7.2B, the largest PE backed IPO ever) and a robust corporate M&A environment signal improving conditions for distributions in 2026, with a majority of GPs expecting to complete more exits this year.

• Continuation vehicles expanding: GP led CVs grew 62% YoY and 40% of GPs plan to explore one in the next 12 to 24 months, though LPs remain lukewarm and will generally tolerate only one per year from a given manager.

• Zombie fund risk rising: Roughly 30% of fund series expected to reraise have not yet done so, and Bain benchmarks the global financial crisis (when failure rates hit ~20%) as the likely reference point for how many will ultimately fail.

• Full potential diligence replacing defensive DD: The report highlights Hg's $6.4 billion OneStream Software take private as a model for integrated commercial, technical, AI, and operational diligence that starts generating value on Day 1 of ownership.

The Wrap

The Bain report makes clear that the private equity industry's new normal is structurally more demanding, not temporarily depressed. Firms that define a repeatable, data backed edge, invest in capabilities (particularly AI and professionalized fundraising), and accelerate EBITDA growth from Day 1 will ride the upper arm of the K. Everyone else faces a slow reckoning. For technology platforms serving this market, the implication is equally direct: the GPs willing to pay for differentiated tools are the ones most desperate to close the gap between 5% and 12%.